Skip to search boxSkip to navigationSkip to main content

Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells

  • Priya Weerasinghe(corresponding author)
    ,
  • Sarathi Hallock
    ,
  • Shou Ching Tang
    ,
  • Benjamin Trump
    ,
  • Andrejs Liepins
*Corresponding author for this work
  • University of Colorado Anschutz Medical Campus
    ,
  • Memorial University of Newfoundland
    ,
  • University of Miami
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

Permeability-glycoprotein (Pgp) positive cells are known to be encoded by the multidrug-resistance gene (MDR1), and characterized by a reduced ability to accumulate drugs. The vinblastin-resistant, Pgp positive CEM-VLB 1000 and its wild type (Pgp-negative and vinblastin-sensitive) counterpart CEM-T4 human leukemia cells, when treated with the alkaloid sanguinarine, were both found to undergo apoptosis at concentrations of 1.5 μg/ml and oncosis/blister cell death (BCD) at concentrations of 12.5 μg/ml. The aim of this study was to assess the ability of sanguinarine to overcome Pgp-mediated multidrug-resistance (MDR), and also to characterize the cell death processes of apoptosis and oncosis (or bimodal cell death) induced by sanguinarine in MDR cells. The cell death processes of apoptosis and oncosis in CEM-VLB 1000 and CEM-T4 cell lines were found to be qualitatively similar when assessed by light microscopy, terminal deoxynucleotidyl transferase (TdT) end-labeling, annexin-V-binding, trypan blue exclusion and western blot analysis. Western blotting revealed an increase in the Bax/Bcl-2 ratio and activation of caspase-3 in apoptosis but not oncosis in both cell lines. The Pgp-positive CEM-VLB 1000 cells and their wild type CEM-T4 cells were both equally sensitive to sanguinarine. Thus, sanguinarine may overcome the phenomenon of Pgp-mediated MDR by inducing apoptosis through increasing the Bax/Bcl-2 ratio and activating caspase-3, and oncosis, which involved neither.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 21-30 (10 pages)

Journal (Volume, Issue Number)

Experimental and Toxicologic Pathology (Volume 58, Issue 1)

Publication milestones

  • Published - 08/15/2006

Publication status

Published - 08/15/2006

ISSN

0940-2993

Publication IDs

  • Scopus: 33746374708
  • PubMed: 16735106

Publication metrics

Metrics

SciVal
citations
40
Scopus
citations
Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
SciVal
FWCI
0.77
SciVal
Author count
5
SciVal
Paper percentile
84

PlumX, opens in new tab

Citation count
46
Captures
10

Funding Details

This work was supported by a Medical Research Council of Canada Grant (MT-13178).
FunderFunding number
MRC
MT-13178